Value of the CEA, SCCA, CYFRA21-1, NSE and D-D combined detection in the diagnosis of lung cancer
Li-fang XU,Ke HU
DOI: https://doi.org/10.3969/j.issn.1009-6663.2017.02.011
2017-01-01
Abstract:Objective To evaluate the clinical value of combined detection of Carcino-embryonic antigen (CEA), squamous cell carcinoma antigen (SCCA), Cytokeratin 19 fragment 21-1 (CYFRA21-1), neuronspecific enolase ( NSE) and D-dimer ( D-D) in patients with lung cancer. Methods The levels of serum CEA, SCCA, CY-FRA21-1, NSE, and plasma D-dimer in 170 lung cancer cases, 44 cases with benign lung benign tumor and 90 healthy controls were detected respectively. The sensitivity and specificity of those markers for the diagnosis of lung cancers were calculated. Results The lung cancer group showed higher serum CEA, SCCA, CYFRA21-1, NSE and plasma D-dimer levels than those in the benign lung tumor group and the healthy control group (P both<0. 05). The levels of serum CEA, NSE and plasma D-dimer at stage Ⅲ/Ⅳ were higher than stageⅠ/Ⅱ(P both<0. 05). The highest sensitivity markers for adenocarcinoma, SCLC and SCC were CEA (68. 4%, 65/9), NSE (71. 4%, 20/28) and CYFRA21-1 (66. 0%, 31/47) respectively. The sensitivity of serum CEA, SCCA, CYFRA21-1, NSE, and plasma D-dimer in the diagnosis of lung cancer was 50. 6%, 37. 6%, 51. 8%, 52. 4% and 62. 4% respectively, and the specificity was 91. 8%, 85. 1%, 87. 3%, 82. 1% and 89. 6%. The combined sensitivity was 85. 3%, but the specificity decreased to 76. 1%. Conclusion The combined detection of serum CEA, SCCA, CYFRA21-1, NSE and plasma D-dimer plays an important role in the diagnosis of lung cancer and is better than single assay.